Shots:

• The P-III SUNRISE 1 (Study 304) study involves assessing of DAYVIGO (lemborexant- 5 or 10 mg) vs an active comparator or PBO in 1-006 patients with insomnia disorder aged 55 years of age or older
• Results of P-III study@ 5/10 mg of DAYVIGO: headache (6.4%- 4.9 % vs 6.2%- 5.3%)- somnolence (4.1%- 7.1% vs 1.9%- 1.5%)- published in JAMA Network Open
• Lemborexant is a candidate targeted for inhibiting orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2) and has also received the US FDA’s approval on Dec 20 - 2019 for patients to treat insomnia and will be available in 90 days post-approval

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance